Global Nano Chemotherapy Market and Clinical Trials Outlook 2022 Report

“Global Nano Chemotherapy Market and Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-nano-chemotherapy-market-and-clinical-trials-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential

Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles

Role of Nanotherapeutics in Various Diseases Treatment
3.1 Nanotherapeutics Approach for Cardiovascular Disease
3.2 Nanotherapeutics Approach for Cancer Therapy
3.3 Nanotherapeutics Approach for Diabetes Treatment
3.4 Nanotherapeutics Approach for Rheumatoid Arthritis

Chemotherapeutics Nanoformulations of Approved Drugs: Clinical Insights and Price Analysis
4.1 Abraxane (Advanced Lung, Pancreatic, Breast Cancers)
4.2 Depocyte (Lymphomtous Meningitis)
4.3 Doxil (Kaposi’s Sarcoma, Ovarian Cancer)
4.4 Marqibo (Acute Myelogenous Leukemia)
4.5 Neulasta (Chemotherapy Induced Neutropenia)
4.6 Oncospar (Acute Lymphoblastic Leukemia)
4.7 Zevalin (Non-Hodgkin Lymphoma)

Chemotherapeutics Nanoformulations in Clinical Trials: Clinical Insight and Mode of Action
5.1 MM-302 (Metastatic Breast Cancer)
5.2 Thermodox (Hepatobiliary Tumors)
5.3 CPX-351 (Acute Myelogenous Leukemia)
5.4 IHL-305 (Solid Tumor Malignancy)
5.5 MM-398 (Metastatic Pancreatic Cancer)
5.6 BIND-014 (Metastatic Prostate Cancer)
5.7 NK-012 (Solid Tumor Malignancy)
5.8 CRLX-101 (Solid Tumor Malignancy and Rectal Cancer)

Global Market Nanotherapeutics Outlook
6.1 Market Scenario of Nanotherapeutics
6.2 Market Size of Nanomedicine

Cancer Nanotherapeutics Market Revenue
7.1 Sales of Nano Chemotherapeutic Drugs
7.2 Top Nanotherapeutics Companies Revenue
7.3 Global Cancer Nanomedicine Clinical Pipeline Overview

Global Nano Chemotherapeutics Market Dynamics
8.1 Favorable Parameters
8.2 Challenges to the Market Growth

Future Perceptive of Nano Chemotherapeutics

Competitive Landscape
10.1 Ablynx
10.2 AMAG
10.3 Amgen
10.4 Celgene
10.5 CytImmune
10.6 Cornerstone
10.7 Delpor
10.8 Ensysce
10.9 MagForce AG
10.10 Merrimack
10.11 Nanotherapeutics
10.12 Nanobiotix
10.13 Nanospectra
10.14 Spectrum pharmaceuticals
10.15 Tarveda

Figure 1-1: Application of Nanotechnology in the Field of Medicine
Figure 1-2: Biomedical Application of Nano chemotherapeutics
Figure 1-3: Nano Chemotherapeutics with Pharmaceutical Potential
Figure 2-1: Limitations to Conventional Chemotherapy Treatment
Figure 3-1: Nanotherapeutics for Heart Disease Treatment
Figure 3-2: Nanotherapeutics Approach in Cancer Therapy
Figure 3-3: Nanotherapeutics Approach for Diabetes Treatment
Figure 3-4: Rheumatoid Arthritis Treatment by Nanotherapeutics
Figure 4-1: Abraxane - Market Price (US$ per Unit Injection) and Patent Expiration Year
Figure 4-2: Cytarabine - Market Price for 20 mg/ml and 100 mg/ml (US$)
Figure 4-3: Doxil and Doxorubicin - Price of Intravenous Solution (US$)
Figure 4-4: Marqibo - Price of Intravenous Solution (US$) and Patent Expiration Year
Figure 4-5: Neulasta - Price for 6 mg/ 0.6 ml and Per Unit Cost (US$)
Figure 4-6: Oncospar - Price for 750 Units/ml and for Per Unit Cost (US$)
Figure 4-7: Zevalin - Price of Intravenous Solution (US$) and Patent Expiration Year
Figure 5-1: Mechanism of Action of MM-302
Figure 5-2: Mechanism of Action of Thermodox and its Mechanical Release
Figure 5-3: Future Development of CPX-351
Figure 5-4: Outsourcing for BIND-014 Clinical Supplies
Figure 5-5: Structure of NK-012 and Release of SN-38 from NK-012
Figure 5-6: Design of a Clinical Trial for CRLX-101
Figure 6-1: Global - Nanomedicine Market (US$ Billion), 2016-2022
Figure 7-1: Sales of Nano Chemotherapeutic Sales (US$, Million), 2016
Figure 7-2: Nano Chemotherapeutics Companies Sales Revenue (US$, Million), 2015
Figure 7-3: Global - Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 7-4: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 7-5: Global - Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 7-6: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-1: Favorable Parameters to Nano Chemotherapeutic Market
Figure 8-2: Challenges to Nano chemotherapeutics Market Growth
Figure 9-1: Future Development Opportunities of Nanomedicine






Table 3-1: Adverse Reactions with andge; 5% Higher Incidence in Neulasta Patients Compared to Placebo

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.